Limits...
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Lee SH, Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, Lee GK, Lee CH, Oh MH, Kim GY, Sung SH, Lee KY, Chang SH, Rho MS, Kim HK, Jung SH, Jang SJ, Cardiopulmonary Pathology Study Group of Korean Society of Pathologis - J Pathol Transl Med (2015)

Bottom Line: We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy.EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey.

Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.

Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

No MeSH data available.


Related in: MedlinePlus

EGFR mutation rates in in-house laboratories. EGFR, epidermal growth factor receptor.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4696529&req=5

f4-jptm-2015-09-14: EGFR mutation rates in in-house laboratories. EGFR, epidermal growth factor receptor.

Mentions: Interestingly, specimens obtained from two in-house laboratories showed low EGFR mutation rates of 16.7% (2/12 specimens) and 9.3% (4/43 specimens) in patients with NSCLC, respectively, and 28.6% (2/7 specimens) and 11.5% (3/26 specimens) in patients with adenocarcinoma and never-smokers (Fig. 4). In brief, one laboratory that detected a 16.7% mutation rate in patients with NSCLC analyzed tumor specimens from 12 patients. Of these 12 patients, 10 had adenocarcinoma, one had large cell carcinoma, and one had NSCLC. Of the 10 patients with adenocarcinoma, seven, two, and one were never-smokers, ex-smokers, and smoker, respectively. All the specimens were obtained by surgical excision and were analyzed by tumor microdissection. The laboratory that detected a 9.3% mutation rate in patients with NSCLC analyzed tumor specimens from 43 patients. Of these 43 patients, 41 had adenocarcinoma, one had NSCLC, and one had squamous cell carcinoma. Of the 41 patients with adenocarcinoma, 25, 6, and 10 were never-smokers, ex-smokers, and smokers, respectively. Of the 43 specimens analyzed in this laboratory, six were surgical excision specimens, 29 were biopsy specimens, and eight were cytology specimens. All 43 specimens were analyzed without tumor microdissection. A total of four EGFR mutations were found, and all of them were adenocarcinoma. They included three never-smokers and one ex-smoker. Moreover, of the four mutations, two were detected in excision specimens and two were detected in biopsy specimens.


Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Lee SH, Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, Lee GK, Lee CH, Oh MH, Kim GY, Sung SH, Lee KY, Chang SH, Rho MS, Kim HK, Jung SH, Jang SJ, Cardiopulmonary Pathology Study Group of Korean Society of Pathologis - J Pathol Transl Med (2015)

EGFR mutation rates in in-house laboratories. EGFR, epidermal growth factor receptor.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4696529&req=5

f4-jptm-2015-09-14: EGFR mutation rates in in-house laboratories. EGFR, epidermal growth factor receptor.
Mentions: Interestingly, specimens obtained from two in-house laboratories showed low EGFR mutation rates of 16.7% (2/12 specimens) and 9.3% (4/43 specimens) in patients with NSCLC, respectively, and 28.6% (2/7 specimens) and 11.5% (3/26 specimens) in patients with adenocarcinoma and never-smokers (Fig. 4). In brief, one laboratory that detected a 16.7% mutation rate in patients with NSCLC analyzed tumor specimens from 12 patients. Of these 12 patients, 10 had adenocarcinoma, one had large cell carcinoma, and one had NSCLC. Of the 10 patients with adenocarcinoma, seven, two, and one were never-smokers, ex-smokers, and smoker, respectively. All the specimens were obtained by surgical excision and were analyzed by tumor microdissection. The laboratory that detected a 9.3% mutation rate in patients with NSCLC analyzed tumor specimens from 43 patients. Of these 43 patients, 41 had adenocarcinoma, one had NSCLC, and one had squamous cell carcinoma. Of the 41 patients with adenocarcinoma, 25, 6, and 10 were never-smokers, ex-smokers, and smokers, respectively. Of the 43 specimens analyzed in this laboratory, six were surgical excision specimens, 29 were biopsy specimens, and eight were cytology specimens. All 43 specimens were analyzed without tumor microdissection. A total of four EGFR mutations were found, and all of them were adenocarcinoma. They included three never-smokers and one ex-smoker. Moreover, of the four mutations, two were detected in excision specimens and two were detected in biopsy specimens.

Bottom Line: We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy.EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey.

Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status.

Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC.

Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

No MeSH data available.


Related in: MedlinePlus